Problematic alcohol use (PAU) is a leading cause of death and disability worldwide. Although 55 genome-wide association studies (GWASs) have identified PAU risk genes, the genetic 56 architecture of this trait is not fully understood. We conducted a proxy-phenotype meta-analysis 57 of PAU combining alcohol use disorder and problematic drinking in 435,563 European-ancestry 58 individuals. We identified 29 independent risk variants, 19 of them novel. PAU was genetically 59 correlated with 138 phenotypes, including substance use and psychiatric traits. Phenome-wide 60 polygenic risk score analysis in an independent biobank sample (BioVU, n=67,589) confirmed 61 the genetic correlations between PAU and substance use and psychiatric disorders. Genetic 62 heritability of PAU was enriched in brain and in genomic conserved and regulatory regions. 63
Alcohol use and alcohol use disorder (AUD) are leading causes of death and disability 69 worldwide [1] . Genome-wide association studies (GWAS) of AUD and problematic drinking 70 measured by different assessments have identified potential risk genes primarily in European 71 populations [2] [3] [4] [5] . Quantity-frequency measures of drinking, for example the Alcohol Use 72
Disorders Identification Test-Consumption (AUDIT-C), which sometimes reflect alcohol 73 consumption in the normal range, differ genetically from AUD and measures of problematic 74 drinking (e.g., the Alcohol Use Disorders Identification Test-Problems [AUDIT-P]), and show a 75 divergent set of genetic correlations [3, 4] . The estimated SNP-based heritability (h 2 ) of AUD 76 ranges from 5.6% to 10.0% [2] [3] [4] [5] . To date, more than ten risk variants have been significantly 77 associated with AUD and AUDIT-P (p < 5 × 10 -8 ). Variants mapped to several risk genes have 78 been detected in multiple studies, including ADH1B (Alcohol Dehydrogenase 1B), ADH1C 79 (Alcohol Dehydrogenase 1C), ALDH2 (Aldehyde Dehydrogenase 2, only in some Asian 80 samples), SLC39A8 (Solute Carrier Family 39 Member 8), GCKR (Glucokinase Regulator), and 81 CRHR1 (Corticotropin Releasing Hormone Receptor 1). In the context of the known extensive 82 polygenicity underlying AUD and AUDIT-P, we anticipate that additional significant risk loci can 83 be identified by increasing sample size; this is the pattern for GWAS of heterogenous complex 84 traits in general also. We can characterize both AUD itself and AUDIT-P, as "problematic 85 alcohol use" (PAU). To identify additional risk variants and enhance our understanding of the 86 genetic architecture of PAU, we conducted genome-wide meta-analysis of AUD and AUDIT-P in 87 435,563 individuals of European ancestry. The understanding of the genetic architecture of PAU 88 in African populations is far behind than Europeans; the largest sample published so far is 89 56,648 in MVP [3] and results have not moved beyond a single genomic region that includes 90
ADH1B. This study only focused on European samples because we cannot achieve a 91 substantial increment in African-ancestry subjects over previous studies. Biobank (UKB). MVP phase1 and phase2 were meta-analyzed, and the result was used for 118 testing the genetic correlation with PGC alcohol dependence. An intermediary meta-analysis 119 (AUD meta) combining MVP phase1, phase2, and PGC was then conducted to measure the 120 genetic correlation with UKB AUDIT-P. Due to the sample overlap between UKB and GSCAN, 121 we used the AUD meta-analysis for Mendelian Randomization (MR) analysis rather than the 122 PAU (i.e., the second) meta-analysis. MTAG, which used the summary data from PAU and 123 DrnkWk (drinks per week) in GSCAN (without 23andMe samples as those data were not made 124 available) as input to increase the power for each trait without introducing bias from sample 125 overlap, returned summary results for PAU and DrnkWk separately. 126 127 Association results for PAU 128 1.07 × 10 -9 , with a minor allele frequency of 0.003), which causes a substitution of histidine for 141 arginine, is in the same codon as rs2066702 (a well-known variant associated with AUD in 142 African populations [3, 8] , but not polymorphic in European populations).This latter association is 143 independent from rs1229984 in ADH1B and rs13125415 (a tag SNP of rs1612735 in MVP 144 phase1 [3]) in ADH1C. The identification of rs75967634 demonstrates the present study's 145 greater power to detect risk variants in this region, beyond the frequently reported 146 ADH1B*rs1229984. 147
Moderate genetic correlation between AUD and alcohol consumption, and also 148 pervasive pleiotropic effects of SNPs, were demonstrated previously [2] [3] [4] . Some of the novel 149 variants (10 out of 19) identified in this study were also associated with other alcohol-related 150 traits, including AUDIT-C score [3] , total AUDIT score [4], and drinks per week (DrnkWk) from 151 the GSCAN study [9] (described below and Supplementary Table 3 ). Rs1402398, close to 152 VRK2, was associated with AUDIT-C score (tagged by rs2683616) [3] ; rs492602 in FUT2 was 153 associated with DrnkWk [9] and total AUDIT score [4]; and rs6421482, rs62250713, rs2533200, 154 rs10717830, rs1783835, rs12296477, rs61974485, and rs72768626 were associated with 155
DrnkWk directly or through tag SNPs in high linkage disequilibrium (LD) [9] . Analysis 156 conditioned on DrnkWk shows that 11 of the 29 independent variants were independently 157 associated with PAU (i.e., not mediated by DrnkWk) ( Supplementary Table 3 Gene-based association analysis identified 66 genes that were associated with PAU 169 at GWS (p < 2.64 × 10 -6 , Supplementary Table 4 ). DRD2, which has been extensively studied in 170 many fields of neuroscience, was among these 66 genes and had been reported in both UKB [4] Factor), and others. Certain genes show associations with multiple traits including previous 176 associations with AUDIT-C (4 genes in MVP phase1, 12 genes in UKB), total AUDIT score (19 177 genes in UKB), and DrnkWk (46 genes in GSCAN, which includes results for DrnkWk after 178
MTAG [10] analysis). 179
Examination of the 66 associated genes for known drug-gene interactions through the 180 Drug Gene Interaction Database v3.0.2 [11] showed 327 interactions between 16 genes and 181 325 drugs ( Supplementary Table 5 ). Of these 16 genes with interactions, DRD2 had the most 182 drug interactions (n = 177), followed by BDNF (n = 68) and PDE4B (n = 36). 183
184

SNP-based h 2 and partitioning heritability enrichment 185
We used LD Score Regression (LDSC) [12] to estimate SNP-based h 2 in the different datasests 186 and the meta-analyses ( Figure 2 ). Because of the unbalanced case/control ratio, we used 187 effective sample size instead of actual sample size in MVP (following the PGC AD GWAS [2]). 188
The h 2 of PAU (the meta result) was 0.068 (se = 0.004). The h 2 of AUD in the MVP meta-189 analysis (phases 1 and 2) was 0.095 (se = 0.006), and was 0.094 (se = 0.005) in the meta- Partitioning heritability enrichment analyses using LDSC [13, 14] showed the most 200 significantly enriched cell type group to be central nervous system (CNS, p = 3.53 × 10 -9 ), 201 followed by adrenal and pancreas (p = 1.89 × 10 -3 ), and immune and hematopoietic (p = 3.82 × 202 10 -3 , Supplementary Figure 4 ). Significant enrichments were also observed in six baseline 203 annotations, including conserved regions, conserved regions with 500bp extended (ext), fetal 204 DHS (DNase I hypersensitive sites) ext, weak enhancers ext, histone mark H3K4me1 ext, and 205 TSS (transcription start site) ext (Supplementary Figure 5 ). We also investigated heritability 206 enrichments using Roadmap data, which contains six annotations (DHS, H3K27ac, H3K4me3, 207 H3K4me1, H3K9ac, and H3K36me3) in a subset of 88 primary cell types and tissues [14, 15] . 208
Significant enrichments were observed for H3K4me1 and DHS in fetal brain, and H3K4me3 in 209 fetal brain and in brain germinal matrix ( Supplementary Table 6 ). Although no heritability 210 enrichment was observed in tissues using gene expression data from GTEx [16] , the top 211 nominally enriched tissues were all in brain (Supplementary Figure 6) . 212 213
Functional enrichments 214
MAGMA tissue expression analysis [17, 18] using GTEx showed significant enrichments in 215 several brain tissues including cerebellum and cortex ( Supplementary Figure 7) . Although no 216 enrichment was observed via MAGMA gene-set analysis using gene-based p-values of all 217 protein-coding genes, the 152 genes prioritized by positional, expression quantitative trait loci 218 (eQTL), and chromatin interaction mapping were enriched in several gene sets, including 219 ethanol metabolic processes ( Supplementary Table 7) . 220 221
Genetic correlations with other traits 222
We estimated the genetic correlations between PAU and 715 publicly available sets of GWAS 223 summary statistics which included 228 published sets and 487 unpublished sets from the UK 224
Biobank. After Bonferroni correction (p < 6.99 × 10 -5 ), 138 traits were significantly correlated 225 with PAU ( Supplementary Table 8 ). Among the 26 published traits, drinks per week showed the 226 highest rg with PAU (rg = 0.77, se = 0.02, p = 3.25 × 10 -265 ), consistent with the overall quantity 227 of alcohol consumed being a key domain of PAU [5, 19] . Several smoking traits and lifetime 228 cannabis use were positively genetically correlated with PAU, consistent with the high 229 comorbidity between alcohol and other substance use disorders in the general population [20] . 230
Among psychiatric disorders, major depressive disorder (MDD, rg = 0.39, se = 0.03, p = 1.43 × 231 10 -40 ) showed the highest genetic correlation with PAU, extending the evidence for the shared 232 genetic contribution to MDD and alcohol-related traits [21, 22] . PAU was positively genetically 233 correlated with risk-taking behavior, insomnia, lung cancer, and other traits, and negatively 234 correlated with cognitive traits and parents' age at death. These finding are in line with the 235 known adverse medical, psychiatric, and social consequences of problem drinking (Figure 3 ). 
Transcriptomic analyses 242
We used S-PrediXcan [23] to predict gene expression and the mediating effects of variation on 243 gene expression on PAU. Forty-eight tissues from GTEx [16] release v7 and whole blood 244 samples from the Depression Genes and Networks study (DGN) [24] were analyzed as 245 reference transcriptomes ( Supplementary Table 9 ). After Bonferroni correction, 103 gene-tissue 246 associations were significant, representing 39 different genes, some of which were identified in 247 multiple tissues ( Supplementary Table 10 ). For example, C1QTNF4 (C1q and tumor necrosis 248 factor related protein 4) was detected in 18 tissues, including brain, gastrointestinal, adipose, 249 and liver. None of the four significant alcohol dehydrogenase genes (ADH1A, ADH1B, ADH4, 250
and ADH5) was associated with expression in brain tissue, but they were associated with 251 expression in other tissues --adipose, thyroid, gastrointestinal and heart. This might be due to 252 the generally low expression level of these genes in brain [25] . These cross-tissue associations 253 indicate that there are widespread functional consequences of PAU-risk-associated genetic 254 variation at the expression level. 255
Although the sample size for tissues used for eQTL analysis limits our ability to detect 256 associations, there are substantial common eQTLs across tissues [16] . Integrating evidence 257 from multiple tissues can increase power to detect genes relative to the tissues tested 258 individually, at least for shared eQTLs. We applied S-MultiXcan [26] to the summary data for 259 PAU using all 48 GTEx tissues as reference transcriptomic data. The expression of 34 genes 260 was significantly associated with PAU, including ADH1B, ADH4, ADH5, C1QTNF4, GCKR, and 261 DRD2 ( Supplementary Table 11 individual's medical record), and top 10 principal components of ancestry. We standardized the 269 PRS so that the odds ratios correspond to a standard deviation increase in the PRS. After 270
Bonferroni correction, 31 of the 1,372 phenotypes tested were significantly associated with PAU 271 PRS, including alcohol-related disorders (OR = 1.46, se = 0.03, p = 3.34 × 10 -40 ), alcoholism 272 (OR = 1.33, se = 0.03, p = 3.85 × 10 -28 ), tobacco use disorder (OR = 1.21, se = 0.01, p = 2.71 × 273 10 -38 ), 6 respiratory conditions, and 17 additional psychiatric conditions ( Supplementary Figure 8 , 274 Supplementary Table 12 ). 275
276
PAU PRS with AD in independent samples 277
We tested the association between PAU PRS and alcohol dependence in three independent 278 samples: the iPSYCH group (ncase = 944, ncontrol = 11,408, neffective = 3,487); University College 279 London (UCL) Psych Array (ncase = 1,698, ncontrol = 1,228, neffective = 2,851); and UCL Core 280 Exome Array (ncase = 637, ncontrol = 9,189, neffective = 2,383). The PAU PRSs were significantly 281 associated with AD in all three samples, with the most variance explained in the UCL Psych 282
Array sample, which includes the most cases (PTbest = 0.001, R 2 = 2.12%, p = 8.64 × 10 -14 ). In 283 the iPSYCH group and UCL Core Exome Array samples, the maximal variance explained was 284 1.61% (PTbest = 0.3, p = 1.87 × 10 -22 ), and 0.77% (PTbest = 5 × 10 -8 , p = 1.65 × 10 -7 ), respectively 285 ( Supplementary Table 13 ). 286
287
Mendelian Randomization 288
We tested the causal effects of liability to exposures on liability to AUD (MVP+PGC), rather than 289 PAU: the UKB AUDIT-P GWAS was excluded to minimize sample overlap with other GWAS for 290 putative exposures. We limited the exposures to those genetically correlated with PAU, and 291 have more than 30 available instruments. There were only 24 independent variants for AUD; 292 therefore the causal effects of liability to AUD on other traits (i.e., bidirectional) were not tested. 293
Among the 13 tested exposures, 12 showed evidence of a causal effect on liability to AUD, the 294 exception being cigarettes per day (Table 2 ). DrnkWk and ever smoked regularly have a 295 positive causal effect on AUD risk by all 3 methods, without violating MR assumptions through 296 horizontal pleiotropy (MR-Egger intercept p > 0.05). General risk tolerance was shown to be 297 causally related to AUD risk, though the estimate could be biased due to horizontal pleiotropy 298 (intercept p = 9.62 × 10 -3 ). MDD, depressed affect neuroticism subcluster, worry neuroticism 299 subcluster, number of sexual partners, and insomnia show evidence of positive causal effects 300 on liability to AUD from at least one method, while cognitive performance and educational 301 attainment show evidence of negative causal effects. 302 
Joint Analysis of PAU and DrnkWk Using MTAG 309
We conducted a joint analysis of PAU and DrnkWk using MTAG, which can increase the power 310 for each trait without introducing bias from sample overlap [10] . MTAG analysis increased the 311 GWAS-equivalent sample size (nEq) for PAU to 514,790, i.e., a 71.1% increase from the original 312 effective sample size (nE = 300,789, n = 435,563) . In this analysis, we observed an increase in 313 the number of independent variants for PAU to 119, 76 of which were conditionally independent 314 ( Supplementary Figure 9 , Supplementary Table 14 ). For DrnkWk, the MTAG analysis increased 315 the nEq to 612,968 from 537,352, which yielded 141 independent variants, 86 of which were 316 conditionally independent ( Supplementary Figure 10 , Supplementary Table 15 ). MTAG analysis 317 increased the observed h 2 of PAU to 0.113 (se = 0.005) from 0.068 (se = 0.004) and of DrnkWk 318 to 0.063 (se = 0.003) from the reported value of 0.042 (se = 0.002, Figure 2) [9]. 319
The MTAG analysis also increased the power for the functional enrichment analysis. 320
MAGMA gene set analysis for PAU after MTAG analysis detected 10 enriched Gene Ontology 321 terms, including 'regulation of nervous system development' (pBonferroni = 8.80 × 10 -4 ), 322
'neurogenesis' (pBonferroni = 0.010), and 'synapse' (pBonferroni = 0.046) ( Supplementary Table 16 ). 323 324 325 326
Discussion 327
We report here a genome-wide meta-analysis of PAU in 435,563 individuals of European 328 ancestry from the MVP, PGC, and UKB datasets. MVP is a mega-biobank that has 329 enrolled >750,000 subjects (for whom genotype data on 313,977 subjects was used in this 330 study), with rich phenotype data assessed by questionnaires and from the EHR. Currently, MVP 331 is the largest single cohort available with diagnostic information on AUD [3, 6] . PGC is a 332 collaborative consortium that has led the effort to collect smaller cohorts with DSM-IV AD [2] . 333 UKB is a population-level cohort with the largest available sample with AUDIT-P data [4] . 334
Our discovery meta-analysis of PAU yielded 29 independent variants, of which 19 were 335 novel, with 0.059 to 0.113 of the phenotypic variance explained in different cohorts or meta-336 analyses. The h 2 in the Phase1-Phase2 MVP meta-analysis was 0.095 (se = 0.006), which was 337 higher than MVP phase1: 0.056 (se = 0.004, in MVP phase1 where only the actual (as opposed 338 to effective) sample size was used) [3] . The h 2 of AD in PGC was 0.098 (se = 0.018), 339 comparable to the reported liability-scale h 2 (0.090, se = 0.019) [2] . Functional and heritability 340 analyses consistently showed enrichments in brain regions and gene expression regulatory 341 regions, providing biological insights into the etiology of PAU. Variation associated with gene 342 expression in the brain is central to PAU risk, a conclusion that is also consistent with our 343 previous GWASs in MVP of both alcohol consumption and AUD diagnosis [3] . The enrichments 344 in regulatory regions point to specific brain tissues relevant to the causative genes; the specific 345 interactions between 16 genes and 325 drugs may provide targets for the development of 346 medications to manage PAU. Potential targets identified include the D2 dopamine receptor 347 (encoded by DRD2) and phosphodiesterase 4B (encoded by PDE4B). The presence of risk 348 variation at these loci also suggests the possibility that they may be "personalized medicine" 349 targets as well. 350
We also found that PAU was significantly genetically correlated with 138 other traits. The 351 top correlations were with substance use and substance-related disorders, MDD, schizophrenia, 352
and several other neuropsychiatric traits. In a conceptually similar analysis, we performed a 353
PheWAS of PAU PRS in BioVU, which confirmed the genetic correlations between PAU and 354 multiple substance use disorders, mood disorders, and other psychiatric traits in an independent 355 sample. We also used MR to infer causal effects of the above traits on liability to AUD (we 356 tested AUD excluding UKB samples to avoid sample overlap) using selected genetic 357 instruments. We found evidence of causal relationships from DrnkWk, ever smoked regularly, 358 MDD, depressed affect subcluster, worry subcluster, number of sexual partners, insomnia, 359 cognitive performance, and educational attainment to AUD risk, while cognitive performance 360 and educational attainment showed protective effects on liability to AUD. For some of these 361 observed effects, such as with schizophrenia, neuroticism, and general risk tolerance, we 362 cannot exclude horizontal pleiotropy among our instrument variables. We could not test the 363 reverse causality of AUD liability on other traits in the absence of large samples for those 364 targeted traits, which are required to draw causal inferences. Thus we cannot rule out the 365 possibility of bidirectional effects, which are plausible for several of these traits (e.g., MDD). 366
The study has other limitations. First, only European populations were included; 367 therefore, the genetic architecture of PAU in other populations remains largely unknown. To 368 date, the largest non-European sample to undergo GWAS for alcohol-related traits is African 369 American (AA), which was reported in the MVP phase1 sample (17,267 cases; 39,381 controls, 370 effective samples size 48,015), with the only associations detected being on chromosome 4 in 371 the ADH gene locus (where several ADH genes map) [3] . Collection of substantial numbers of 372 non-European subjects requires a concerted effort from our research field. Second, despite the 373 high genetic correlation between AUD and AUDIT-P, they are not identical traits. We conducted 374 a meta-analysis of the two traits to increase the power for the association study of PAU, 375 consequently, associations specific to AUD or AUDIT-P could have been attenuated. Third, 376 there was no opportunity for replication of the individual novel variants. Because the variants 377 were detected in more than 430,000 subjects and have small effect sizes, a replication sample 378 with adequate power would also have to be very large, and no such sample is currently 379 available. To validate the findings, we conducted PRS analyses in three independent cohorts, 380 which showed strong association with AUD. Although this indicates that our study had adequate 381 power for variant detection, it does not address the validity of the individual variants discovered. 382 This is the largest GWAS study of PAU so far. Previous work has shown that the genetic 383 architecture of AUD (and PAU) differs substantially from that of alcohol consumption [2] [3] [4] . 384
There have been larger studies of alcohol quantity-frequency measures [9, 36] ; alcohol 385 consumption data are available in many EHRs, thus they were included in many studies of other 386 primary traits, like cardiac disease. AUD diagnoses are collected much less commonly. The 3-387
item AUDIT-C is a widely-used measure of alcohol consumption often available in EHRs, but 388 the full 10-item AUDIT, which allows the assessment of AUDIT-P, is not as widely available. 389
Despite the high genetic correlation between, for example, PAU and DrnkWk (rg=0.77), very 390 different patterns of genetic correlation and pleiotropy have been observed via LDSC and other 391 methods for these different kinds of indices of alcohol use [2] [3] [4] [5] . PAU captures pathological 392 alcohol use: physiological dependence and/or significant medical consequences. 393
Quantity/frequency measures may capture alcohol use that is in the normal, or anyway 394 nonpathological, range. As such, we argue that although quantity/frequency measures are 395 important for understanding the biology of habitual alcohol use, PAU is the more important, and 396 more clearly pathological, trait. These circumstances underscore the importance of assembling 397 a large GWAS sample of PAU to inform the biology of PAU, and our study moves towards this 398 goal via the identification of numerous previously-unidentified risk loci: we increased known 399 PAU loci from 10 to 29, nearly tripling our knowledge of specific risk regions. Similarly, we 400 identified 66 gene-based associations, of which 46 were novel -again roughly tripling current 401 knowledge. MTAG analysis increased locus discovery to 119, representing 76 independent loci, 402 by levering information from DrnkWk [9]. By the same token, we provide a major increment in 403 information about the biology of PAU, providing considerable fodder for future in-vitro and 404 animal studies, which will be required to delineate the biology and function associated with each 405 risk variant. We anticipate that this knowledge may lead to improvements in treatment and 406 treatment personalization, a major ultimate goal of the work. Affairs (VA), enrollment for which began in 2011 and is ongoing. Phenotypic data were collected 413 using questionnaires and the VA electronic health records (EHR), and a blood sample was 414 obtained from each participant for genetic studies. Two phases of genotypic data have been 415 released and were included in this study. MVP phase1 contains 353,948 subjects, of whom 416 202,004 European Americans (EA) with AUD diagnoses were included in a previous GWAS and 417 the summary statistics were used in this study [3] . MVP phase2 released data on another 418 108,416 subjects, of whom 65,387 EAs with AUD diagnosis information were included in this 419 study. Following the same procedures as for MVP phase1, participants with at least one 420 inpatient or two outpatient alcohol-related ICD-9/10 codes from 2000 to 2018 were assigned a 421 diagnosis of AUD. 422
Ethics statement: The Central VA Institutional Review Board (IRB) and site-specific IRBs 423 approved the MVP study. All relevant ethical regulations for work with human subjects were 424 followed in the conduct of the study and informed consent was obtained from all participants. 425
Genotyping for both phases of MVP was performed using a customized Affymetrix 426 Biobank Array. Imputation and quality control methods for MVP phase1 were described in detail 427
in Kranzler et al. [3] . Similar methods were used for MVP phase2. Before imputation, phase2 428 subjects or SNPs with genotype call rate < 0.9 or high heterozygosity were removed, leaving 429 108,416 subjects and 668,324 SNPs. Imputation for MVP phase2 was done separately from 430 phase1; both were performed with EAGLE2 [37] and Minimac3 [38] using 1000 Genomes 431 Project phase 3 data [39] as the reference panel. Imputed genotypes with posterior probability ≥ 432 0.9 were transferred to best guess genotypes (the rest were treated as missing genotype calls). 433
A total of 6,635,093 SNPs with INFO scores > 0.7, genotype call rates or best guess rates > 434 0.95, Hardy Weinberg equilibrium p value < 1 × 10 −6 , minor allele frequency (MAF) > 0.001 were 435 remained for GWAS. 436
We removed subjects with mismatched genotypic and phenotypic sex and one subject 437 randomly from each pair of related individuals (kinship coefficient threshold = 0.0884), leaving 438 107,438 phase2 subjects for subsequent analyses. We used the same processes as MVP 439 phase1 to define EAs. First, we ran principal components analysis (PCA) on 74,827 common 440
SNPs (MAF > 0.05) shared by MVP and the 1000 Genomes phase 3 reference panels using 441
FastPCA [40] . Then we clustered each participant into the nearest reference population 442 according to the Euclidean distances between the participant and the centers of the 5 reference 443 populations using the first 10 PCs. A second PCA was performed for participants who were 444 clustered to the reference European population (EUR), and outliers were removed if any of the 445 first 10 PCs were > 3 standard deviations from the mean, leaving 67,268 EA subjects. 446
Individuals < 22 or > 90 years of age and those with a missing AUD diagnosis were 447 removed from the analyses, leaving 65,387 phase2 EAs (11,337 cases; 54,050 controls). 448 GWAS was then performed on the MVP phase2 dataset. We used logistic regression 449 implemented in PLINK v1.90b4.4 [41] for the AUD GWAS correcting for age, sex, and the first 450 10 PCs. 451 452 PGC summary statistics. We used the 46,568 European ancestry subjects (11,569 cases and 453 34,999 controls) from 27 cohorts that were analyzed by the Psychiatric Genomics Consortium 454 (PGC). The phenotype was lifetime DSM-IV diagnosis of alcohol dependence (AD). The 455 summary data were downloaded from the PGC website (https://www.med.unc.edu/pgc/) with full 456 agreement to the PGC conditions. Allele frequencies were not reported in the summary data. 457
We used allele frequencies from the 1000 Genome European sample as proxy measures in 458 PGC for some downstream analyses. 459 460 UK Biobank summary statistics. The UK Biobank (UKB) included 121,604 White-British 461 unrelated subjects with available AUDIT-P scores. Past-year AUDIT-P was assessed by 7 462 questions: 1). Frequency of inability to cease drinking; 2). Frequency of failure to fulfil normal 463 expectations due to drinking alcohol; 3). Frequency of needing morning drink of alcohol after 464 heavy drinking session; 4). Frequency of feeling guilt or remorse after drinking alcohol; 5). 465
Frequency of memory loss due to drinking alcohol; 6). Ever been injured or injured someone 466 else through drinking alcohol; 7). Ever had known person concerned about, or recommend 467 reduction of, alcohol consumption. The AUDIT-P was log10-transformed for GWAS (see ref [4] 468 for details). We removed SNPs with INFO < 0.7 or call rate < 0.95. 469 470 Meta-analyses. Meta-analyses were performed using METAL [42] . The meta-analysis within 471 MVP (for the purpose of genetic correlation analysis with PGC AD) was conducted using an 472 inverse variance weighted method because the two subsets were from the same cohort. The 473 meta-analyses for AUD (MVP+PGC) and PAU (MVP+PGC+UKB) were performed using the 474 sample size weighted method. Given the unbalanced ratios of cases to controls in MVP 475 samples, we calculated effective sample sizes for meta-analysis following the approach used by 476 the PGC: The calculated effective sample sizes in MVP and reported effective sample sizes in PGC were 479 used in meta-analyses and all downstream analyses. AUDIT-P in UKB is a continuous trait, so 480 we used actual sample sizes for that trait. For the AUD meta-analysis, variants present in only 481 one sample (except MVP phase1 which is much larger than the others) or with heterogeneity 482 test p-value < 5 × 10 -8 were removed, leaving 7,003,540 variants. For the PAU meta-analysis, 483
variants present in only one sample (except MVP phase1 or UKB) or with heterogeneity test p-484 value < 5 × 10 -8 and variants with effective sample size < 45,118 (15% of the total effective 485 sample size) were removed, leaving 14,069,427 variants. 486 487 AUD polygenic risk score in UKB. We calculated AUD polygenic risk scores (PRS) for each of 488 the 82,930 unrelated subjects in UKB who had AUDIT-P information [7] . A PRS was calculated 489
as the sum of the number of effective alleles with p-values less than a given threshold, weighted 490 by the effect sizes from AUD meta-analysis (MVP+PGC). We analyzed 10 p-value thresholds: 5 491 × 10 -8 , 1 × 10 -7 , 1 × 10 -6 , 1 × 10 -5 , 1 × 10 -4 , 0.001, 0.05, 0.3, 0.5, and 1, and clumped the AUD 492 summary data by LD with r 2 < 0.3 in a 500 kb window. Then we tested the association between 493 AUD PRS and AUDIT-P, corrected for age, sex, and 10 PCs. The analysis was performed using 494 -2 [43] . 495 496 Independent variants and conditional analyses. We identified the independent variant (p < 5 497 × 10 −8 ) in each locus (1 Mb genomic window) based on the smallest p value and r 2 < 0.1 with 498 other independent variants. Variants with p < 1 × 10 −8 and r 2 > 0.1 with respect to the 499 independent variants were assigned to the independent variant's clump. Any two independent 500 variants less than 1 Mb apart whose clumped regions overlapped were merged into one locus. 501
PRSice
Given the known long-range LD for the ADH gene cluster on chromosome 4, we defined 502 chr4q23-q24 (~97.2 Mb -102.6 Mb) as one locus. When multiple independent variants were 503 present in a locus, we ran conditional analyses using GCTA-COJO [44] to define conditionally 504 independent variants. For each variant other than the most significant one (index), we tested the 505 marginal associations conditioning on the index variant using Europeans (n = 503) from the 506 1000 Genomes as the LD reference sample. Variants with significant marginal associations (p < 507 5 × 10 −8 ) were defined as conditionally independent variants (i.e., independent when 508 conditioned on other variants in the region) and subject to another round of conditional analyses 509 for each significant association. 510
For the conditionally independent variants for AUD or PAU, we also conducted a multi-511 trait analysis conditioning on GSCAN drinks per week [9] using GCTA-mtCOJO [45] to identify 512 variants associated with AUD or PAU, but not drinks per week, i.e., not alcohol consumption 513 alone. Europeans from the 1000 Genomes were used as the LD reference. For variants missing 514 in GSCAN, we used proxy variants (p < 5 × 10 −8 ) in high LD with the locus for analyses. 515
Whereas conditional analyses require the beta (effect size) and standard error, we calculated 516 these using Z-scores (z), allele frequency (p) and sample size (n) from the meta-analyses [46]: Gene-based association analysis. Gene-based association analysis for PAU was performed 520 using MAGMA implemented in FUMA [17, 18] , which uses a multiple regression approach to 521 detect multi-marker effects that account for SNP p-values and LD between markers. We used 522 default settings to analyze 18,952 autosomal genes, with p < 2.64 × 10 −6 (0. We conducted portioning h 2 enrichment analyses for PAU using LDSC in different 535 models [13, 14] . First, a baseline model consisting of 52 functional categories was analyzed, 536 which included genomic features (coding, intron, UTR etc), regulatory annotations (promoter, 537 enhancer etc), epigenomic annotations (H3K27ac, H3K4me1, H3K3me3 etc) and others (see 538 ref [13] for details, Supplementary Figure 5 ). We then analyzed cell type group h 2 enrichments 539 with 10 cell types: central nervous system (CNS), adrenal and pancreas, immune and 540 hematopoietic, skeletal muscle, gastrointestinal, liver, cardiovascular, connective tissue and 541 bone, kidney, and other (see ref [13] for details, Supplementary Figure 4 ). Third, we used LDSC 542 to test for enriched heritability in regions surrounding genes with the highest tissue-specific 543 expression using 53 human tissue or cell type RNA-seq data from the Genotype-Tissue 544
Expression Project (GTEx) [16] , or enriched heritability in epigenetic markers from 396 human 545 epigenetic annotations (six features in a subset of 88 primary cell types or tissues) from the 546 Roadmap Epigenomics Consortium [15] (see ref [14] for details, Supplementary Figure 6 , 547 Supplementary Table 6 ). For each model, the number of tested annotations was used to 548 calculate a Bonferroni corrected p-value < 0.05 as a significance threshold. 549 550 Gene-set and functional enrichment. We performed gene-set analysis for PAU for curated 551 gene sets and Gene Ontology (GO) terms using MAGMA [17, 18] . We then used MAGMA for 552 gene-property analyses to test the relationships between tissue-specific gene expression 553 profiles and PAU-gene associations. We analyzed gene expression data from 53 GTEx (v7) 554 tissues. We also performed gene-set analysis on the 152 prioritized genes using MAGMA. Gene 555 sets with adjusted p-value < 0.05 were considered as significant. 556 557 Genetic correlation. We estimated the genetic correlation (rg) between traits using LDSC [48] . 558
For PAU, we estimated the rg with 218 published traits in LD Hub [49] , 487 unpublished traits 559 from the UK Biobank (integrated in LD Hub), and recently published psychiatric and behavioral 560 traits [9, 30, [32] [33] [34] [35] [50] [51] [52] [53] [54] , bringing the total number of tested traits to 715 (Supplementary 561 downloaded from the PredictDB repository (http://predictdb.org/, 2018-01-08 release). Only 573 individuals of European ancestry in GTEx were analyzed. S-PrediXcan was performed for each 574 of the 49 tissues (48 from GTEx and 1 from DGN), for a total of 254,345 gene-tissue pairs. 575
Significant association was determined by Bonferroni correction (p < 1.97 × 10 -7 ). 576
Considering the limited eQTL sample size for any single tissue and the substantial 577 sharing of eQTLs across tissues, we applied S-MultiXcan [26] , which integrates evidence across 578 multiple tissues using multivariate regression to improve association detection. Forty-eight 579 tissues from GTEx were analyzed jointly. The threshold for condition number of eigenvalues 580 was set to 30 when truncating singular value decomposition (SVD) components. In total, 25,626 581 genes were tested in S-MultiXcan, leading to a significant p-value threshold of 1.95 × 10 -6 582 (0.05/25,626). 583 584 PAU PRS for phenome-wide associations. Polygenic scores were generated using PRS-CS 585
[56] on all genotyped individuals of European descent (n = 67,588) in Vanderbilt University 586
Medical Center's EHR-linked biobank, BioVU. PRS-CS uses a Bayesian framework to model 587 linkage disequilibrium from an external reference set and a continuous shrinkage prior on SNP 588 effect sizes. We used 1000 Genomes Project Phase 3 European sample [39] as the LD 589 reference. Additionally, we used the PRS-CS-auto option, which allows the software to learn the 590 continuous shrinkage prior from the data. Polygenic scores were constructed from PRS-CS-auto 591 adjusted summary statistics containing 811,292 SNPs. All individuals used for polygenic scoring 592 were genotyped on the Illumina Multi-Ethnic Global Array (MEGA). Genotypes were filtered for 593 SNP (95%) and individual (98%) call rates, sex discrepancies, and excessive heterozygosity. 594 significant associations with genotyping batch were removed. Genetic ancestry was determined 596 by principal component analysis performed using EIGENSTRAT [57] . Imputation was completed 597 using the Michigan Imputation Server [38] and the Haplotype Reference Consortium [58] as the 598 reference panel. Genotypes were then converted to hard calls, and filtered for SNP imputation 599 quality (R 2 > 0.3), individual missingness (>2%), SNP missingness (>2%), minor allele frequency 600 (<1%) and Hardy-Weinberg Equilibrium (p > 1 × 10 -10 ). The resulting dataset contained 601 9,330,483 SNPs on 67,588 individuals of European ancestry. 602
We conducted a phenome-wide association study (PheWAS) [59] of the PAU PRS, by 603
fitting a logistic regression model to 1,372 case/control phenotypes to estimate the odds of each 604 diagnosis given the PAU polygenic score, controlling for sex, median age across the medical 605 record, top 10 principal components of ancestry, and genotyping batch. We required the 606 presence of at least two International Classification of Disease (ICD) codes that mapped to a 607
PheWAS disease category (Phecode Map 1.2) to assign "case" status. A phenotype was 608 required to have at least 100 cases to be included in the analysis. PheWAS analyses were run 609 using the PheWAS R package [60] . Bonferroni correction was applied to test for significance (p 610 < 0.05/1,372). 611 612 PAU PRS in independent samples. We calculated PAU PRS in three independent samples, 613
where we tested the association between PAU PRS and AD, corrected for age, sex, and 10 614
PCs. Ten p-value thresholds were applied in all samples. 615 iPSYCH Group. DNA samples for cases and controls were obtained from newborn bloodspots 616 linked to population registry data [61] . Cases were identified with the ICD-10 code F10.2 (AD; n 617 = 944); controls were from the iPSYCH group (n = 11,408; neffective = 3,487)). The iPSYCH 618 sample was genotyped on the Psych Array (Illumina, San Diego, CA, US). GWAS QC, 619
